Literature DB >> 28219869

[RNA interference of HERC4 inhibits proliferation, apoptosis and migration of cervical cancer Hela cells].

Min Wei1, Yan-Ling Zhang, Lan Chen, Cui-Xia Cai, Han-Duo Wang.   

Abstract

OBJECTIVE: To explore the effects of silencing HERC4 on the proliferation, apoptosis, and migration of cervical cancer cell line Hela and the possible molecular mechanisms.
METHODS: Three HERC4-specific small interfering RNAs (siRNAs) were transfected into Hela cells, and HERC4 expression in the cells was examined with Western blotting. CCK-8 assay, annexin V-FITC/PI assay, and wound healing assay were used to assess the effect of HERC4 silencing on the proliferation, apoptosis and migration ability of Hela cells. The expression levels of cyclin D1 and Bcl-2 in the cells were detected using Western blotting.
RESULTS: Transfection of siRNA-3 resulted in significantly decreased HERC4 protein expression (P<0.01). HERC4 silencing by siRNA-3 markedly suppressed the proliferation and migration of Hela cells, increased the apoptosis rate (P<0.01) and reduced the expression levels of cyclin D1 and Bcl-2 (P<0.01).
CONCLUSION: Silencing of HERC4 efficiently inhibits the proliferation, migration, and invasion of Hela cells in vitro, and the underlying mechanisms may involve the down-regulation of cyclin D1 and Bcl-2.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28219869      PMCID: PMC6779654     

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  21 in total

1.  Emerging therapies targeting the ubiquitin proteasome system in cancer.

Authors:  Nathaniel M Weathington; Rama K Mallampalli
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

2.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

3.  RN181 suppresses hepatocellular carcinoma growth by inhibition of the ERK/MAPK pathway.

Authors:  Suihai Wang; Xiang Huang; Yue Li; Haimiao Lao; Ying Zhang; Huimin Dong; Weiwen Xu; Ji-Liang Li; Ming Li
Journal:  Hepatology       Date:  2011-05-02       Impact factor: 17.425

4.  siRNA agents inhibit oncogene expression and attenuate human tumor cell growth.

Authors:  James Q Yin; Jingsong Gao; Ronguang Shao; Wang-Ni Tian; Jianping Wang; Yinsheng Wan
Journal:  J Exp Ther Oncol       Date:  2003 Jul-Aug

Review 5.  Ubiquitin-conjugating enzyme E2C: a potential cancer biomarker.

Authors:  Chanlu Xie; Chris Powell; Mu Yao; Jianmin Wu; Qihan Dong
Journal:  Int J Biochem Cell Biol       Date:  2013-12-17       Impact factor: 5.085

6.  Disruption of the ubiquitin ligase HERC4 causes defects in spermatozoon maturation and impaired fertility.

Authors:  Clara I Rodriguez; Colin L Stewart
Journal:  Dev Biol       Date:  2007-10-04       Impact factor: 3.582

Review 7.  The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer.

Authors:  Robert Z Orlowski; E Claire Dees
Journal:  Breast Cancer Res       Date:  2002-08-14       Impact factor: 6.466

8.  Epidemiological Investigation and Risk Factors for Cervical Lesions: Cervical Cancer Screening Among Women in Rural Areas of Henan Province China.

Authors:  Qingwei Zhang; Wenyan Xie; Feng Wang; Rong Hong Li; Lina Cui; Huifen Wang; Xiuhong Fu; Jiayu Song
Journal:  Med Sci Monit       Date:  2016-06-01

9.  Biomarkers in cervical cancer.

Authors:  Eun-Kyoung Yim; Jong-Sup Park
Journal:  Biomark Insights       Date:  2007-02-07

10.  The expression and clinical significance of HERC4 in breast cancer.

Authors:  Hui Zhou; Rong Shi; Min Wei; Wen-Ling Zheng; Jue-Yu Zhou; Wen-Li Ma
Journal:  Cancer Cell Int       Date:  2013-11-14       Impact factor: 5.722

View more
  1 in total

1.  SAV1, regulated by HERC4, inhibits the proliferation, migration, and invasion of hepatocellular carcinoma.

Authors:  Fang Huang; Xujie Tang; Tao Sun; Gangyi Wang; Qingjing Ru; Yi Zheng
Journal:  Transl Cancer Res       Date:  2021-01       Impact factor: 1.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.